Niclosamide Inhibits Cell Growth and Enhances Drug Sensitivity of Hepatocellular Carcinoma Cells via STAT3 Signaling Pathway
Authors:
Open Access
- 1 January 2018
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 9 (22) , 4150-4155
Abstract
Aims: Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide, with a high mortality rate at advanced stages. In this study, we investigated the effect of niclosamide on cell growth and drug sensitivity in human HCC and elucidated the underlying mechanism.Keywords
This publication has 26 references indexed in Scilit:
- Targeting the IL-6/JAK/STAT3 signalling axis in cancerNature Reviews Clinical Oncology, 2018
- Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathwayBiochemical and Biophysical Research Communications, 2016
- Survivin in survival of hepatocellular carcinomaCancer Letters, 2016
- Cardamonin induces apoptosis by suppressing STAT3 signaling pathway in glioblastoma stem cellsTumor Biology, 2015
- Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibitionThe Prostate, 2015
- WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancerOncogene, 2014
- Multi-targeted therapy of cancer by niclosamide: A new application for an old drugCancer Letters, 2014
- Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinomaBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2013
- Hepatocellular carcinomaThe Lancet, 2012
- In vitro trypanocidal activity of the anti-helminthic drug niclosamideExperimental Parasitology, 2008